Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-05-03

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for buprenorphine and naloxone from Mylan Pharmaceuticals, supporting changes to the product's label under the ANDA path…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)